Trial Profile
Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary) ; Measles mumps and rubella virus vaccine-(Priorix)
- Indications Chickenpox; Measles; Mumps; Rubella
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 05 Jul 2007 Status changed from in progress to completed.
- 17 Jul 2006 Status changed from initiated to in progress
- 05 Nov 2005 New trial record.